Patient-Centric Data Capture Fuels Growth of Target RWE Longitudinal, Real-World Dermatology Studies
- kenashman
- May 8
- 1 min read
By Target RWE 7 May 2025
Real-world evidence (RWE) leader, Target RWE, announced updates from its longitudinal dermatology study of more than 7,000 enrolled patients with two poster presentations on patients with Hidradenitis Suppurativa (HS) at the American Academy of Dermatology (AAD) annual meeting in Orlando, FL, March 7-11, 2025.
Target RWE's dermatology study has experienced substantial growth since its launch in 2019, becoming one of the most comprehensive patient registries in dermatology. It covers various diseases including atopic dermatitis (AD), alopecia areata (AA), hidradenitis suppurativa (HS), chronic spontaneous urticaria (CSU), and vitiligo. The study goes beyond unstructured and structured electronic medical record data by additionally capturing real-world data directly from patients and physicians through patient-reported outcome measures (PROs) and clinician-reported outcomes (ClinROs). Target RWE's real-world data supports translational research, biomarker development from collected biosamples, and additionally captures clinically relevant scores, including the Validated Investigator Global Assessment (vIGA).
